semaglutide esophagus [TUSOM Severe reflux oesophagitis caused by

While pooled data from the SURPASS clinical trial programme indicate that tirzepatide does not increase the risk of major cardiovascular events [61], definitive conclusions regarding its cardiovascular profile should await the results of SURPASS-CVOT, with its completion anticipated in late 2024 [60]

Combining Semaglutide with another GLP-1 receptor agonist, such as Liraglutide or Dulaglutide, is generally avoided because the overlapping effects dont add extra benefit and may increase side effects

Careful monitoring may be required to avoid this complication

Provider Perspective : Some providers prefer tirzepatide for patients struggling with weight loss goals or requiring tighter glycemic control